Patents Assigned to H. Lundbeck A/S
  • Halogenated quinazolin-THF-amines as PDE1 inhibitors
    Patent number: 10526319
    Abstract: The present invention provides halogenated quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 7, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
  • 1 H-pyrazolo[4,3-B]pyridines as PDE1 inhibitors
    Patent number: 10512632
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 24, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
    Patent number: 10513524
    Abstract: The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 24, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Kate Wen, Yazhou Wang
  • Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
    Patent number: 10501427
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 10, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10487142
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: November 26, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Agent, uses and methods for treatment
    Patent number: 10479835
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: November 19, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward Van Den Brink, Paul Parren, Rob De Jong
  • Antibodies specific for hyperphosphorylated tau and methods of use
    Patent number: 10472415
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 12, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjærgaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific to pyroglutamated A?
    Patent number: 10472414
    Abstract: The present invention relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands. Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use in therapeutic purposes.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 12, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Søren Christensen, Lone Helboe
  • Anti-sortilin antibodies, uses and methods for treatment
    Patent number: 10428147
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 1, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Søren Christensen, Jan Egebjerg, Jeffrey B. Stavenhagen, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES
    Publication number: 20190282571
    Abstract: The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides phannaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 19, 2019
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasumssen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
    Patent number: 10383849
    Abstract: The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients suffering from a CNS disease, in particular patients with Parkinson's disease, wherein balance, gait or movement is impaired.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: August 20, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Inge E. M. de Jong, Aaron Kucinski, Martin Sarter
  • Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
    Patent number: 10376506
    Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 13, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Connie Sanchez Morillo, Gennady N. Smagin
  • Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
    Patent number: 10364286
    Abstract: The invention relates to a novel use of monoclonal anti-alpha-synuclein antibodies. The antibodies can be used to prevent tau aggregation and thereby treating tauopathies such as Alzheimer's disease.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Karina Fog, Jeppe Falsig Pedersen
  • Antibodies for the treatment of synucleinopathy
    Patent number: 10364285
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 30, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Antibodies for the treatment of synucleinopathy
    Patent number: 10358484
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 23, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Antibodies for the treatment of synucleinopathy
    Patent number: 10358482
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 23, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Antibodies for the treatment of synucleinopathy
    Patent number: 10358483
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 23, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors
    Patent number: 10351561
    Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 16, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgard, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl, Mauro Marigo
  • COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS
    Publication number: 20190151309
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 23, 2019
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., H. LUNDBECK A/S
    Inventors: Kenji MAEDA, Mai NAKAMURA
  • Vortioxetine pyroglutamate
    Patent number: 10287261
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: May 14, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb